Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer
NCT00491816
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Erlotinib with neoadjuvant chemotherapy
Sponsor
University of Kansas Medical Center
Collaborators
[object Object]